Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
German foreign minister heads to China to talk rare-earth exports - 2Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- 3Blue Origin’s New Glenn rocket landed its booster on a barge at sea – an achievement that will broaden the commercial spaceflight market
- 4Air superiority and long-range strikes: what China's war games say about how it might assault Taiwan
- 5Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- New materials, old physics – the science behind how your winter jacket keeps you warm
- Manual for Financial plan Agreeable PC
- This Tiny Neon Frog Dwells in the Clouds
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- Figure out How to Track and Anticipate Future Cd Rates
- A Manual for Nations to Head out To
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
